Mỹ cho phép dùng thuốc Remdesivir trong điều trị bệnh COVID-19

(TTXVN/Vietnam+) 09:51 23/10/2020

Thông báo của Cơ quan Quản lý Thực phẩm và Dược phẩm Mỹ (FDA) ngày 22/10 cho biết, cơ quan này đã cấp phép sử dụng thuốc Remdesivir (do công ty Gilead Sciences phát triển) trong điều trị bệnh viêm đường hô hấp COVID-19.

IsSpNzXhurvhu43Eg+G7p+G7pzo0w7rFqGrFqeG7jeG6vzQg4buOw4M14bq7xKnDtDXDusSp4buBw7o14bq94burw7Xhu4k1xanEqcaw4bub4bq7NeG7pOG6v+G7j+G6veG6v+G7p2rhu7Vq4bulNcWp4bulw7TDteG7iTXDqmpoxrA1xanhu6VtNeG6uWnDtcSpNeG6usOU4bu0SuG6vC03w6MiL8SpNyAiw7o14bq74buNxIPhu6fhu6c6NMO6xKjhur/Eg+G6vTQgxajEqcahw7Xhu4k14bq54bqvw7Q14bq74butxIM14bq6cDXDucawxIPDtTXDmcaw4bqzw7U14buNw4E1xajEqXnhurs1w7rEqWXhu4814bu14bqxNeG6vHZz4bq7NcO6xKll4buPNeG7jsODNVvhu4rhurzEgl01w7Xhu4nhurFBNTg4Lzc2NeG6u8Spw7Q14bq5amfFqT414bq7cDXDucawxIPDtTXDteG6sUE1w6rhurU14bq7Y8O6NcO6xKnhu4HDujXhu6fDvTXhur3hu7HDteG7iTXFqcSpxrDhu5vhurs14buk4bq/4buP4bq94bq/4bunauG7tWrhu6U1W+G6vcO0NeG6u8ahw7Xhu4k1xalBNeG7iGrhu43hur/Eg+G6vTXhu6bhurtq4bq/w7Xhurvhur/hu6c1w7rEqeG6r8WpNcWp4bulasOtw7VdNcWp4bulw7TDteG7iTXDqmpoxrA1xanhu6VtNeG6uWnDtcSpNeG7tWpm4buPNcOqdnLDteG7iTXEqcahNcSpY8O6NeG6usOU4bu0SuG6vC03w6N7Ii/DuiAiw7o14bq74buNxIPhu6fhu6c6NMO64bq4w7Thur1BNCAiauG7j+G7iTXhurvhu43Eg+G7p+G7pzo04bq74buP4bunLcO6xKnDtMWpw7Q0NcWpasWp4buN4bq/OjThu47DgzXhurvEqcO0NcO6xKnhu4HDujXhur3hu6vDteG7iTXFqcSpxrDhu5vhurs14buk4bq/4buP4bq94bq/4bunauG7tWrhu6U1xanhu6XDtMO14buJNcOqamjGsDXFqeG7pW014bq5acO1xKk14bq6w5Thu7RK4bq8LTfDozXEqWzDtcSpNeG6s8O1xKk1NzQ14bun4bul4bq7OjQvL2p74bq5xIPDtMWpxKnEg8O1xKnEqcO0xIN74bu1w7Uvw7Xhur/hu7fhu6cvODZhOC834bqh4bqh4bq9w6E2w6PDoTbDocOjxanDo8Ojw6A44buNN3vhu7fhur/hurnDujQ1xIPhu43FqTo04buOw4M14bq7xKnDtDXDusSp4buBw7o14bq94burw7Xhu4k1xanEqcaw4bub4bq7NeG7pOG6v+G7j+G6veG6v+G7p2rhu7Vq4bulNcWp4bulw7TDteG7iTXDqmpoxrA1xanhu6VtNeG6uWnDtcSpNeG6usOU4bu0SuG6vC03w6M0NeG6vcSDxanEgy3DusSpw7TFqcO0LcO04bulauG7iWrDtcSD4buNLeG7p+G7peG6uzo0xKnFqcWpw7rhu6cpLy/hurvhur3DtWrhu4/hu4l74bu1auG6v8Wpw7XEg+G7j8O64buNxrDhu6d74bu1w7UvxanDoDg2L8aww7rhu43DtMSD4bq94bq/4bq9L+G6ucO0w7PDtMOyxIMvODY4Nl83Nl84OS/hu6Xhur/hu4/hur3hur/hu6dq4bu1auG7pXvDs8O64bq/4buJNDUvIMWoxKnGsOG7m+G6uzXhu6Thur/hu4/hur3hur/hu6dq4bu1auG7pT414bun4bqzw7U1w7rEqWXhu4814bq74butxIM14buIauG7jeG6v8SD4bq9NeG7puG6u2rhur/DteG6u+G6v+G7p3s1W+G6ssO1xKkpNcSCw5pdIi/DuiAiw7o14bq74buNxIPhu6fhu6c6NMO64bq4w7Thur1BNCDFqMSpxqHDteG7iTXhurnhuq/DtDXhurvhu63EgzXhu4rhurzEgjXDtWbGsDXhu6Xhu5d7NeG7tWpp4bq7NeG6u2PDujXDusSp4buBw7o1xanhu6Vmw7U1w6p2c+G6uzXDqnbEgzXhu6XEgzXhur15xIM1xanhu6Vmw7U1OTXFqcSpw701w7Xhu4nEqWpp4buPNcO14buJw6nGsDXDtcSpambDtTXhurvhu5E1w6rhu5tqNeG6u8Spd8O14buJPjXFqeG7pcO0w7Xhu4k1w6rhu5E14bq74buRNeG7j+G7o8WpNcWpxKnDvTXDteG7icSpamnhu4814bq9w7Q14bu0amnDtTVANcWpZzXDmcaw4bub4bq7NeG7iWrEgzXFqeG6sWo1xanhu6VzeyIvw7ogIsO6NeG6u+G7jcSD4bun4bunOjTDuuG6uMO04bq9QTQgxajEqeG6v8O0NcO14buJxKlqZsO1NeG6u3fGsDXDqnZz4bq7NeG6u8ahw7Xhu4k14bq54bubNcWp4bulZsO1NcWo4bq3w7o14bq7xKlrNUE1xKnhu5nhurs1w5Xhur/hu7c14bq+w7Xhu4nhu43Eg8O14bq9NcSp4budajXDqmTGsDXFqcSp4bqvw7Xhu4k1w7XhurFBPjXDtcSp4buzw7Xhu4k14bq5acO1xKk1w7XEqWLDtTXDqnZz4bq7NeG6veG7q8O14buJNcWpxKnGsOG7m+G6uzXhu6Thur/hu4/hur3hur/hu6dq4bu1auG7pTXhurvhu5E1xanhu5vhurs1w6rhu6M1xKnhu51qNcO6xKnhu7Hhurs1xanhu6XGsMO14buJNeG6uWzDtcSpNcO1xKnEg8O1xKk1xKlww7U1w6E1LTXhuqE1w7Xhu4nhurFBNeG7p8O0NeG7tXFqNcO1xKnhu7PDteG7iTXhurlpw7XEqTXDtcSpYsO1NcO14bqtw7Xhu4k1w6p2c+G6uzXhur3hu6vDteG7iTXhu4lq4bqzNeG6vXZz4bq7eyIvw7ogIsO6NeG6u+G7jcSD4bun4bunOjTDuuG6uMO04bq9QTQgw5Xhu4nEqWpmw7U14bq7d8awNeG6u+G7r8O14buJNeG6u8Spw7Q1xanEqWNBNeG7pOG6v+G7j+G6veG6v+G7p2rhu7Vq4bulNeG7jeG6seG7jzXhu4lq4bqz4buPNcOyxKnhurM1w7XDosO14buJNeG6uWnDtcSpNcO1xKliw7U1w7rEqeG6s2o14bq94burw7Xhu4k1w6pnw7U1xanhu6VzNcWpxKl0NcO04bu5QTXhu7XhurE14bq74buRNcWpxKnDrTXhu43hurHhu4814buJauG6s+G7jzXhurvhurM1w7Xhu4nGsEE14bq7cDXFqcO9NeG7tcO0w7Xhu4l7Ii/DuiAiw7o14bq74buNxIPhu6fhu6c6NMO64bq4w7Thur1BNCDhu4hq4buN4bq/xIPhur014bum4bq7auG6v8O14bq74bq/4bunNcO1xKljw7U14buP4bq3w7XEqTXDqmJBNeG7jeG6sTXDusSpdnDDteG7iTXDusSp4bqvw7o1w6pqaMawNcWp4bulbTXhurrDlOG7tErhurwtN8OjNcOqZMawNcWpambDtTXhu7XhurE14bq9xrBBNcO1xKljxak14bq7xKnDtDXFqXFqNcO1xINBNcOqdnPhurs14buOw4M14bq7xKljw7o1w7XEqcSRw7V7NeG6usahw7Xhu4k1xalBNeG6ueG6sUE1xanhu5U1xKlBNeG7teG7mcO14buJNeG6u+G7kTXFqcSpw601w6rhuq/DujV3w7Xhu4k1w6p2c+G6uzXDtcSpxrA14bq7ZMawNeG6u+G7rcSDNcWpxKlnNeG7iWpxajXDquG7m2o14bu1cWo14buNw7ThurdqNcWpxKnGsOG7m+G6uzXDteG6sUE1w7Xhu4nEg0E1xanhu6XDtMO14buJNcWpxKnhuq/DteG7iTU3NnsiL8O6ICLDujXhurvhu43Eg+G7p+G7pzo0w7rhurjDtOG6vUE0IOG6usSp4butNcWpbeG6u8SpNcOyambhu4814buIauG6r+G7jzXDquG7m+G6uzXDqmpoxrA1xKnhurHDtcSpNVvhurrhur7DlF014buIauG7jeG6v8SD4bq9NeG7puG6u2rhur/DteG6u+G6v+G7pz41xqHDteG7iTXhurzEg8O1auG6v+G7jTXDlOKAmeG6vMSDQTXDssSp4bqpw7Xhu4k1w6ptw7XEqTXhurvGocO14buJNcWpQTXDqsSDw7Xhu4k14bq74buRNeG7p+G6q8O1NcWpxKnGsOG7m+G6uzXDqsOtNcOqamjGsDXFqeG7pW014bq7xKnDtDXDtcSp4buzw7Xhu4k14bq5acO1xKk1w7XEqWLDtTXFqcSpa+G6u8SpNcSpc8O6eyIvw7ogIsO6NeG6u+G7jcSD4bun4bunOjTDuuG6uMO04bq9QTQgxKhqacO1NeG7iGrhu43hur/Eg+G6vTXDqsSDw7Xhu4k1xalrw7XEqTXFqcO04bqvw7U14bu1cWo14bq74bqv4bq7NeG6u8ahw7Xhu4k1xalBNeG6ueG6s8O0NcSpasOt4buPNcWpdjXDtcSpYsO1NeG7tWg14buPd+G6uzXDusSpazU5ezc4NjXGr+G7puG6vDXhurvEqcO0NeG7j+G7oWo14bq5acO1xKk1w7XEqWLDtTXDqmpoxrA1xanhu6VtNcOhNcO14buJ4bqxQXs14bq64bqv4bq7NcO1dnHhurs1w7rEqeG6r8WpNcWp4bulasOtw7U14bu14bqxNcO1xKnhu7PDteG7iTXDqnDDtTXhu7VtNeG7j8awxIM1xanhu6V54bq7NcWpamfDujXFqeG7pcO0w7Xhu4k14bq6xKlrw7XEqTXDusSp4butNeG7jsODPjXhurnEg8O0NeG7ieG7neG7jzXhurvhurM14bq74bqv4bq7NeG6uWnDtcSpNeG7tWppw7U14bq74butxIM14bq7ecawNeG6u8SpamfDtTXhurlqw7XEqT414bun4buFNcO6xKnhurNqNcWp4bul4bqzNTh7OWE2Ncav4bum4bq8NeG6u8Spw7Q14buP4bujxak1w6pzxak1xanEqcaw4bub4bq7NcOqamjGsDXFqeG7pW014bq94bqxajXDoTXDteG7ieG6sUF7Ii/DuiAiw7o14bq74buNxIPhu6fhu6c6NMO64bq4w7Thur1BNCDhu6Thur/hu4/hur3hur/hu6dq4bu1auG7pTXhu43hurE14buP4bujxak1xanhu6XDtMO14buJNcO1xKnhu7PDteG7iTXhu43DtOG6t2o1xanEqcaw4bub4bq7NcOqdnPhurs14bunw7014bq94buxw7Xhu4k1w6pqaMawNcWp4bulbTXhurvEqcO0NcWo4bufw7Xhu4k1xanEqeG7m8O14buJNeG6vMO0w7XEg+G7jeG6vTXFqOG7pcaw4buPw7o1w7LEqWo1xqHDteG7iTXhurltNcO1xKlqw6zhu4814bq6w5Thu7RK4bq8LTfDo3sveyIvw7ogIsO6NeG6u+G7jcSD4bun4bunOjTDusSCxrDFqcSpw7Thu6U0IFvFqMWo4bu44bu0w5Uv4bu0auG6v8Wpw7XEg+G7jytdIi/DuiA=